Prognostic factors in non-small cell lung cancer: a decade of progress.
about
Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancerCan gene expression profiling predict survival for patients with squamous cell carcinoma of the lung?Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysisA comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancerPemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review)XPC mRNA level may predict relapse in never-smokers with non-small cell lung cancersHigh-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patientsEffect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patientsCombining clinical, pathological, and demographic factors refines prognosis of lung cancer: a population-based studyPrognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyondCirculating microRNAs in relation to EGFR status and survival of lung adenocarcinoma in female non-smokersA laboratory prognostic index model for patients with advanced non-small cell lung cancerA comprehensive peptidome profiling technology for the identification of early detection biomarkers for lung adenocarcinomaReporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.Reduced transthyretin expression in sera of lung cancer.Comparing single-agent with doublet chemotherapy in first-line treatment of advanced non-small cell lung cancer with performance status 2: a meta-analysis.Recursive Partitioning Analysis of Mediastinal N2 Lymph Node Involvement with Selected Biological Markers in Operable Non-small Cell Lung Cancer: A Correlative StudyPET/CT Assessment of Response to Therapy: Tumor Change Measurement, Truth Data, and Error.Peak oxygen consumption and long-term all-cause mortality in nonsmall cell lung cancerFactors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer.An association between DNA repair gene polymorphisms and survival in patients with resected non-small cell lung cancer.Flexible modeling improves assessment of prognostic value of C-reactive protein in advanced non-small cell lung cancer.Protein signature for non-small cell lung cancer prognosis.Early lung cancer in the elderly: sublobar resection provides equivalent long-term survival in comparison with lobectomy.The level of serum carcinoembryonic antigen is a surrogate marker for the efficacy of EGFR-TKIs but is not an indication of acquired resistance to EGFR-TKIs in NSCLC patients with EGFR mutationsmDIFFERENTIAL SERUM LEVEL OF SPECIFIC HAPTOGLOBIN ISOFORMS IN SMALL CELL LUNG CANCER.A dual role for KRT81: a miR-SNP associated with recurrence in non-small-cell lung cancer and a novel marker of squamous cell lung carcinoma.C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinomaPoor prognosis patients with inoperable locally advanced NSCLC and large tumors benefit from palliative chemoradiotherapy: a subset analysis from a randomized clinical phase III trial.Pulmonary atelectasis and survival in advanced non-small cell lung carcinoma.Epidemiology of lung cancer prognosis: quantity and quality of life.Circulating DNA: diagnostic tool and predictive marker for overall survival of NSCLC patientsMiR-495 regulates proliferation and migration in NSCLC by targeting MTA3.Semi-quantitative investigation of primary tumor and bone metastasis in lung cancer patients using the PET-CT approach.Smoking and prognostic factors in an observational setting in patients with advanced non-small cell lung carcinomaMolecular imaging in cancer treatment.Clinical significance and role of lymphatic vessel invasion as a major prognostic implication in non-small cell lung cancer: a meta-analysis.Eligibility for bevacizumab as an independent prognostic factor for patients with advanced non-squamous non-small cell lung cancer: a retrospective cohort study.Stereological Evaluation of Tumor Regression Rates in Lung Cancer Using CT Via the Cavalieri Method.Usefulness of serum carcinoembryonic antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective cohort study
P2860
Q24657740-97C95962-7FB4-4E85-A29F-AE1EF7E2E8A2Q24801522-DCB55C27-2F7B-4D2B-9861-4D44D861AE3FQ26769728-A6E7A0FA-3F1A-4907-8903-BF3B304C57EDQ26865662-1D76FAA7-6EAB-47F2-AD5A-44B014291924Q28081243-CE397D10-F4AD-4622-A962-D403E3C3FB65Q28246216-8391B373-0647-4FCE-9735-5AF1334C0554Q28256642-35147076-5F80-492D-9A10-A7A1DCD0916CQ28382908-177968D0-F14E-4311-A063-C8CC8B1C672AQ28386520-624E4D3F-C38F-4C9E-956C-75631898AEBCQ28388487-80A370CE-99CD-44BD-A9CA-E59425EB1A46Q28391728-E518D039-848D-4A62-A120-0C42AD4CD101Q28542513-C8EB2B04-B36B-4A42-AC38-F406FAB5582CQ28741189-51614879-145C-4445-ABD0-061A2A81CEE2Q30514241-F6675726-5083-4D1B-9526-65651BF84C11Q33293388-996FAD7F-8B8A-49FF-BBAE-0E9FEAF58CEFQ33421926-07D71850-9612-4C1A-8B51-14453A2CB664Q33491562-8F095CB5-431C-4C63-9750-064580B145A8Q33517102-C7CC395D-53D2-4010-A5F7-8BEBC26C82EAQ33589369-583A4E89-0E1E-4488-92A0-4EEC034DFC0CQ33600434-103075F9-B492-4891-A98B-79E331344D2FQ33781302-40DE9C97-05AE-4946-92D8-CFC2A20CE7CFQ33783059-0288C986-04C6-4841-8619-E98775A985F4Q33785608-5CA9C463-585B-454F-8067-D80956216C87Q33799220-C1059A68-572F-4D1D-B162-1EDE3CBD3202Q33857865-3938145E-13A6-4633-AF4F-D20A35682788Q33893239-505E4C6E-CFF9-4F4A-9598-0B237D0A6635Q33974932-8078B43A-ED6D-496D-A152-124E02114C56Q34031219-54C19EFF-988A-4E4F-817B-66A1EFA89B4CQ34041802-DE63AC95-63B7-4DCD-87E2-1ADDB4F6EF9BQ34128113-57E38D94-0AC1-4EEA-8D1A-EC10CA897C69Q34135295-0D4F2A89-D5C0-4DE1-BE32-206B787C0ABBQ34305528-DA21E04A-DC34-48CE-BA65-BA25F27AC7E7Q34389043-1C1BE9FB-F50C-4A22-9B5B-969C3B20CF9FQ34414975-84A4E505-5CDA-4C15-ADD0-15BF93B01A0BQ34487100-78595235-3BE7-4CD9-A614-4E70A22FAAC7Q34496670-9CB542CB-CE24-4AE2-837A-EEF6A1646663Q34534484-04DCEC7C-3569-4AE4-937A-EEC8533A78EFQ34651916-F3ADD0F4-837B-472B-949B-1E433BF48B56Q34667988-CB5594D0-B960-4A2D-B8C5-9186AFCF8681Q34734470-9A3D87FA-9AEC-4244-9779-99A2398A1E4D
P2860
Prognostic factors in non-small cell lung cancer: a decade of progress.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Prognostic factors in non-small cell lung cancer: a decade of progress.
@ast
Prognostic factors in non-small cell lung cancer: a decade of progress.
@en
Prognostic factors in non-small cell lung cancer: a decade of progress.
@nl
type
label
Prognostic factors in non-small cell lung cancer: a decade of progress.
@ast
Prognostic factors in non-small cell lung cancer: a decade of progress.
@en
Prognostic factors in non-small cell lung cancer: a decade of progress.
@nl
prefLabel
Prognostic factors in non-small cell lung cancer: a decade of progress.
@ast
Prognostic factors in non-small cell lung cancer: a decade of progress.
@en
Prognostic factors in non-small cell lung cancer: a decade of progress.
@nl
P2093
P356
P1433
P1476
Prognostic factors in non-small cell lung cancer: a decade of progress.
@en
P2093
Diane Davies
Michael D Brundage
William J Mackillop
P304
P356
10.1378/CHEST.122.3.1037
P407
P577
2002-09-01T00:00:00Z